Oncology

Next generation sequencing of multiple genes for oncology testing can be challenging and time-consuming. A rapid, user-friendly protocol resolves the bottlenecks.

Find a product for my lab

Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder
Devyser Placeholder

Devyser Placeholder

Oncology

Next generation sequencing of multiple genes for oncology testing can be challenging and time-consuming. A rapid, user-friendly protocol resolves the bottlenecks.

Contact me

The implementation of NGS assays into clinical routine use can be limited by the complexity of the associated protocols and data analysis. Large, comprehensive oncology gene panels may include genes that are not relevant or of unknown significance to the disease being tested by the laboratory. This can result in higher sequencing costs and significantly increases the complexity of data analysis and clinical decision making due to the increased number of detected variants of unknown significance as well as other incidental findings.

Devyser BRCA and Devyser HBOC kits are rapid targeted NGS library preparation assays intended for the detection of variants in BRCA1, BRCA2, and 12 additional genes where mutations are known to significantly increase the risk of developing breast and ovarian cancer.

Devyser BRCA and Devyser HBOC can be used simultaneously as a first-line protocol for the analysis of 14 highly relevant hereditary breast and ovarian cancer (HBOC) associated genes.

Devyser HBOC kit can also be used as a stand-alone follow-up after negative BRCA testing with Devyser BRCA.

Related articles

Booklet: Hereditary Cancer Testing

Whitepaper: NGS: Full Gene Sequencing of BRCA1 and BRCA2

Scientific publications

Detection of a novel germline PALB2 deletion in a young woman with hereditary breast cancer: When the patient's phenotype history doesn't Lie. De Angelis, C. et al., Front. Oncol., 24 February 2021

Salvage lymphadenectomy in recurrent ovarian cancerpatients: Analysis of clinical outcome and BRCA1/2 gene mutational status. V. Gallotta et al., European Journal of Surgical Oncology. Volume 46, Issue 7, July 2020, Pages 1327-1333.

Spectrum of germline BRCA1 and BRCA2 variants identified in 2351 ovarian and breast cancer patients referring to a reference cancer hospital of Rome, C. Santonocito et al., Cancers (Basel). 2020 May 19;12(5):1286.

Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by high resolution melting analysis. Minucci et al., Mol Biol Rep. 2020 Feb;47(2):1513-1520.

Prognostic factors value of germline and somatic brca inpatients undergoing surgery for recurrent ovarian cancer with liver metastases. V. Gallotta et al., Eur J Surg Oncol. 2019 Nov; 45(11):2096-2102.

BRCA1 and BRCA2 Testing through Next Generation Sequencingin a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenicand Unknown Clinical Significance Variants. Concolino P. et al., Int J Mol Sci.2019 Jul; 20(14): 3442.

Detection of BRCA 1/2 large genomic rearrangements in breast and ovarian cancer patients: an overview on the current methods. Paola Concolino & Ettore Capoluongo. Expert review of molecular diagnostics. Volume19, 2019 - Issue 9.

Novel BRCA1 large genomic rearrangements in italian breast/ovarian cancer Patients. R. Rizza et al., Mol Diagn Ther. 2019 Feb;23(1):121-126.

A comprehensive BRCA1/2 NGS pipeline for an immediate copy number variation (CNV) detection in breast and ovarian cancer molecular diagnosis. P. Concolino et al., Clinica Chimica Acta. Volume 480, May 2018, Pages 173-179.

High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report. A. Costella et al., Human Genome Variation volume 5, Article number: 10 (2018).

Evaluation of a next-generation sequencing assay for BRCA1and BRCA2 Mutation Detection. G. Capone et al., The Journal of Molecular Diagnostics. 20 Oct 2017, 20(1):87-94.

No items found.